After leading Pfizer through the frantic race to develop the first FDA-approved COVID-19 vaccine, CEO Albert Bourla has set his sights on a new, arguably more difficult moonshot. “We saved the world from Covid, now we’ll save the world from cancer,” Bourla told Fortune Editor-in-Chief Alyson Shontell, outlining the company’s massive pivot toward oncology following the pandemic.
This ambition is backed by a historic reallocation of capital. Pfizer reinvested its pandemic-era windfalls into a $23 billion spending spree in 2023, targeting new business development opportunities to secure the company’s future.
